Novo Nordisk 

Compound Sharing

Novo Nordisk 

Compound Sharing

||

PYY analogue - Y2 selective

Category
ID
Amount per vial
PYY
NNC0165-1273
1000 nmol

PYY is secreted from the L-cells in the intestine in response to a meal. The PYY1-36 is rapidly cleaved to PYY3-36 and this analogue bind and activate selectively the Y2 receptor. PYY3-36 is also quite rapidly degraded to the inactive version PYY3-34. The Y2 receptor belongs to a the NPY family of receptors that comprise four receptors Y1, Y2 Y4 and Y5. It is a satiety factor and lowers food intake as well as glucose regulation. In combination with GLP-1 which is also co-secreted from the L-cells the effects are potentiated.

NNC0165-1273 is a modified PYY3-36 analogue with increased selectivity for Y2 against Y1, Y4 and Y5 receptors. It is modified in the C-terminal position 35 where the arginine has been replaced with beta-homo-arginine. In the Østergaard et al. 2018 reference listed in the reference section, NNC0165-1273 is peptide 29. The C-terminal modification results in a slightly lower Y2 activity, but much improved selectivity and it also stabilizes against C-terminal degradation.

Selected calculated properties for NNC0165-1273 and PYY3-36 (NNC0165-0020).
PropertyNNC0165-1273PYY3-36
MW (Da)4163.54049.5
pI (calculated)8.58.5
Seauence substitutions
(compared to reference)
35-beta-homo-arginine-
Extinsion coefficient (calculated, 280nm)1146011460

2D sketch of NNC0165-1273. Compared to native PYY, NNC0165-1273 has a beta-homo-arginine in position 35.
2D sketch of the sequence of native PYY (3-36)-NH2.

NPY receptor scintillation proximity assays (SPA) were performed using cell membrane preparations from cell lines expressing one of the human Y1, Y2, Y4, or Y5 receptors. Reduction of cyclic adenosine monophosphate (cAMP) through Gi-coupled Y receptor activation was measured using human embryonic kidney (HEK) 293 cells stably expressing one of the human Y1, Y2, Y4, or Y5 receptors and a cAMP-sensitive calcium channel. See the Østergaard et al. 2018 reference listed in the reference list for further data and details on the experimental setup of the in vitro assays.


Receptor binding data (Ki, nM)
CompoundY1Y2Y4Y5
PYY3-36400.40133.2
NNC0165-127310002.025001300

Potency data (EC50, nM)
PYY3-36161.0>307.9
NNC0165-1273>10005.0>1000790
Y1, Y2, Y4, Y5 are NPY receptor subtype 1,2,4, and 5, respectively

For in vivo data, please see the Jones et al. 2019 reference listed in the reference section.

The reference compound to NNC0165-1273 is PYY3-36 (NNC0165-0020). Please indicate in the 'Purpose' field when you request NNC0165-1273 if you would like to have PYY3-36 (NNC0165-0020) included in your shipment

The PYY peptides are easily dissolved in MilliQ water or DMSO. Avoid stock solutions at neutral pH since this is close to pI. Peptides and proteins have a tendency to adhere to glass and plastic surfaces. This may at low concentration impact the actual amount in solution. To minimize this unspecific adherence, adding detergents or inert proteins like e.g., ovalbumin or other serum albumins to the solution can minimize this phenomenon. In case albumins are added to peptide/protein solutions, ensure that the albumins are free of any proteases, but be aware that it will affect the apparent potency and affinity in in vitro assays in case a fatty acid is attached to the compound.

Østergaard S et al.
Design of Y2 Receptor Selective and Proteolytically Stable PYY3−36 Analogues
J Med Chem. 2018;61(23):10519-10530
Jones ES et al.
Modified peptide YY molecule attenuates the activity of NPY/AgRP neurons and reduces food intake in male mice
Endocrinology. 2019;160(11):2737-2747